AX-2025-020799 · Thymosin α1 · CPC lot CPC-2504-M9819

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	97.56	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	2.44	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — deamidated Asn (+1 Da)	1.01	% area	≤ 1.00	FAIL
Identity — theoretical monoisotopic mass	calculated from molecular formula	3106.5493	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	3106.5564	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.3	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	88.44	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	86.28	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	10.95	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	9.448	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	94.5	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	5.80	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.00	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.76	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.16	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.97	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	11.90	min	11.94 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.06	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	62,629	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated Asn (+1 Da)	1.63	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 62,629, and skew follows the reported asymmetry factor of 1.06. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.01 % impurity against a 97.56 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Thymosin α1 — main peak	11.90	4,741,718	97.56	—
2	deamidated Asn (+1 Da)	11.58	49,089	1.01	+0.984
3	aspartimide (−18 Da)	12.29	44,229	0.91	-18.011
4	truncated (1-24)	10.74	13,123	0.27	-487.229
5	des-acetyl Tα1 (−42 Da)	11.27	12,151	0.25	-42.011
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 3106.5493 Da, computed from C129H215N33O55. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 3106.5564 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
5+	622.3171	622.3186	0.0015	8.8
4+	777.6446	777.6464	0.0018	60.2
3+	1036.5237	1036.5261	0.0024	100.0
2+	1554.2819	1554.2855	0.0036	61.6

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	5.80
Counter-ion (acetate)	ion chromatography	5.00
Residual solvent + inorganic residue	estimated	0.76
Total peptide content	by difference	88.44
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.5	97.56	divergence -0.06 pp vs batch median
Total impurities (% area)	2.50	2.44
Largest single impurity (% area)	not stated	1.01
Water (%)	3.3	5.80
Counter-ion (%)	8.3	5.00
Peptide content (%w/w)	87.8	88.44
Endotoxin (EU/mg)	not stated	0.16
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 1 d) → laboratory (hand-carried, 2 d) → assay.
Assay date: 14 Sep 2025
Submitted to the index: 10 Oct 2025
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

round_numbers10 Oct 2025

The certificate for lot CPC-2504-M9819 states purity as a round figure. Integrated areas do not land on halves, so this is either a rounded presentation of a real integration or a release specification carried into the result field. Independent measurement here is 97.56 %, which is consistent with either.

benford_check10 Oct 2025

Nothing on this record contradicts the declaration. Purity 97.56 %, largest single impurity deamidated Asn (+1 Da) at 1.01 %, mass balance closed.

Section 7

Related records

Same batch — lot CPC-2504-M9819 n=1

This is the only report on this lot. One report is not a batch characterisation.

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Thymosin α1 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041996	AMB	AMB-2511-B5683	VendorInvestigate	2026-Q2	99.31	4.20	91.2	Buyer-sourced	0	PASS
AX-2026-041995	AMB	AMB-2511-B5683	PeptideMeter	2026-Q2	98.86	4.00	104.5	Buyer-sourced	0	PASS
AX-2026-041998	AMB	AMB-2511-B5683	Nordanalyt	2026-Q2	99.08	3.83	—	Buyer-sourced	0	PASS
AX-2026-043232	SGN	SGN-2512-Y9621	Janoshik	2026-Q2	99.42	6.88	89.1	Buyer-sourced	1	MARGINAL
AX-2026-041999	AMB	AMB-2511-B5683	Medutest	2026-Q2	99.93	3.95	102.2	Supplier-supplied	1	MARGINAL
AX-2026-041997	AMB	AMB-2511-B5683	PeptideMeter	2026-Q2	99.11	4.26	104.3	Buyer-sourced	0	PASS
AX-2026-041442	QYB	QYB-2511-V5408	Kestrel	2026-Q1	99.82	2.35	96.1	Buyer-sourced	0	PASS
AX-2026-041438	QYB	QYB-2511-V5408	Janoshik	2026-Q1	99.80	2.70	105.2	Buyer-sourced	0	PASS

Other recent CPC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043319	BPC-157	CPC-2602-W1610	Medutest	2026-Q3	98.82	2.88	103.5	Buyer-sourced	2	MARGINAL
AX-2026-043295	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.34	5.17	106.3	Buyer-sourced	0	FAIL
AX-2026-043288	Tirzepatide	CPC-2607-L1516	Janoshik	2026-Q3	96.89	5.11	101.1	Laboratory-retained	0	FAIL
AX-2026-043327	N-Acetyl Semax Amide	CPC-2602-D1905	Nordanalyt	2026-Q3	99.05	5.67	90.6	Buyer-sourced	1	FAIL
AX-2026-043328	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.49	6.83	100.9	Supplier-supplied	0	PASS
AX-2026-043257	L-Carnosine	CPC-2603-G9615	VendorInvestigate	2026-Q3	98.20	10.41	102.2	Buyer-sourced	0	FAIL
AX-2026-043297	Liraglutide	CPC-2602-G9942	Janoshik	2026-Q3	97.01	4.95	103.5	Buyer-sourced	0	FAIL
AX-2026-043331	N-Acetyl Semax Amide	CPC-2602-D1905	Janoshik	2026-Q3	99.46	6.22	—	Supplier-supplied	0	PASS